Biophytis SA
PAR:ALBPS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biophytis SA
Total Current Assets
Biophytis SA
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biophytis SA
PAR:ALBPS
|
Total Current Assets
€3.8m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Current Assets
€222.5m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
7%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Current Assets
€144.3m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
8%
|
|
|
Inventiva SA
PAR:IVA
|
Total Current Assets
€172.8m
|
CAGR 3-Years
18%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Current Assets
$212.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-4%
|
|
|
Abivax SA
PAR:ABVX
|
Total Current Assets
€170.7m
|
CAGR 3-Years
68%
|
CAGR 5-Years
35%
|
CAGR 10-Years
15%
|
|
Biophytis SA
Glance View
Biophytis SA is a holding company. The company is headquartered in Paris, Ile-De-France and currently employs 24 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
See Also
What is Biophytis SA's Total Current Assets?
Total Current Assets
3.8m
EUR
Based on the financial report for Jun 30, 2025, Biophytis SA's Total Current Assets amounts to 3.8m EUR.
What is Biophytis SA's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
-25%
Over the last year, the Total Current Assets growth was -33%. The average annual Total Current Assets growth rates for Biophytis SA have been -50% over the past three years , -25% over the past five years .
